Introduction
Every year more than 10 million people worldwide experi ence a stroke, 1 and depression is a common complication with an 8 times higher incidence than in the general popula tion in the first months after the acute event. 2 Comorbid de pression seems to have a negative impact on stroke patients' recovery, mortality and quality of life, [2] [3] [4] [5] but the link between depression and stroke is still largely unknown. It is possible that brain inflammation contributes to the development of depressive symptoms following stroke. 6, 7 During the first hours following stroke, proinflammatory cytokines are re leased in the brain, [7] [8] [9] and they peak after 3-4 weeks. 10 These cytokines may activate the hypothalamus-pituitary-adrenal axis, resulting in increased adrenocorticotropic hormone and cortisol levels 11 and elevated conversion of tryptophan into kynurenine instead of serotonin. Hereby the synthesis and availability of serotonin in the brain will be reduced, and this may induce depressive symptoms. 6 The depression immedi ately following stroke may thus be pathogenically different from depression occurring later after stroke.
Owing to the inflammatory component in the pathogen esis, it has recently been suggested that antiinflammatory medications, such as acetylsalicylic acid (ASA), nonsteroid antiinflammatory drugs (NSAIDs) and statins, may decrease the risk for depression. 12, 13 Both ASA and statins are used routinely after ischemic stroke, but to date, only 2 studies have examined the association between statin use and risk for depression after stroke and have reported conflicting findings. 14, 15 In the present study, we examined the hypothesis that anti inflammatory treatment with ASA, NSAIDs and statins pre scribed during firsttime stroke would be associated with decreased risk for subsequent depression. Based on the abovementioned inflammatory mechanisms, we hypothe sized that antiinflammatory medication would mainly influ ence depression developing immediately after stroke. Also, as studies have shown that both poststroke levels of C reactive protein, an acute phase protein, and depression are greater particularly in patients with ischemic stroke, 16 we fur ther hypothesized than any influence of antiinflammatory treatment on depression would be greatest in patients with ischemic stroke or in patients with the most severe strokes. Consequently, we explored associations between anti inflammatories and time of depression onset, stroke subtypes and disease severity in patients with stroke. The association between antiinflammatories and time of depression onset was also explored in a nonstroke population with a similar age and sex distribution.
Methods

Study population
We identified all patients in Denmark admitted to hospital with a firsttime stroke diagnosis between Jan. 1, 2001 , and Dec. 31, 2011 , from the Danish National Patient Register using the following International Classification of Diseases (ICD)10 codes: I61 intracerebral hemorrhage, I63 cerebral in farction, I64 unspecified stroke, and G45 transient ischemic attack (TIA). The Danish National Patient Register was estab lished in 1977 and stores data on diagnosis, treatments and dates from all somatic and psychiatric hospital admissions for every emergency, in and outpatient contact, 17 which al lowed us to identify incident stroke cases in the register. We established a comparable nonstroke population with similar sex, age and municipality as patients at the time of stroke diagnosis using information from the Danish Civil Registra tion System. The Danish Data Inspection approved the study. All data were retrieved from administrative registers, thus in formed consent was not required of participants.
Anti-inflammatory treatment
All prescriptions of ASA, NSAIDs, or statins from Jan. 1, 1995, to Dec. 31, 2014, were obtained from the Danish Pre scription Register using Anatomic Therapeutic Chemical (ATC) Classification codes B01AC06, B01AC56, N02BA01 and N02BA51 for ASA; N01A for NSAIDs; and C10AA for statins. Antiinflammatory treatment was measured from 5 years preceding stroke or study entry to either 1) the end of the first month after stroke or study entry, or 2) to the end of the first year after stroke.
Assessment of depression
We obtained information on diagnoses of depression and filled prescriptions for antidepressant medication bewteen Jan. 1, 1995, and Dec. 31, 2014 , from the National Patient Regis ter, and we confirmed any fatal cases of stroke from the Danish Cause of Death Register using ICD10 codes F31.3-33 and 34.1 and from the Danish Prescription Register using ATC code N06A. Earlyonset depression was defined as a hospital contact with depression or filling a prescription for antidepressants 1 month to 1 year after study entry. Late onset depression was defined as a hospital contact with de pression or filling a prescription for antidepressants 1 year or more after study entry. Of the cases of depression diagnosed after study entry, 0.93% were based solely on an ICD10 code, 15.19% were based on both an ICD10 code and an ATC code, and 83.88% were based solely on an ATC code.
Covariates
We included information on basic sociodemographic charac teristics, somatic and other psychiatric comorbidity, previous episodes of depression and selected types of medication as co variates. Further, data on stroke severity were available for a subgroup of patients. Education was categorized as basic edu cation (grade 7-9), medium education (high school diploma or vocational degree), higher education (postsecondary de gree), or unknown based on data from the Integrated Data base for Labor Market Research. Cohabitation status based on data from the Danish Civil Registration System was categor ized as single or living with a partner. From the National Patient Registry and the Danish Prescription Register, we obtained information on both hospital admission and medica tion for somatic or psychiatric comorbidity during the 5 years preceding inclusion in the study. We defined our somatic and psychi atric covariates as somatic/psychiatric status at the time of inclusion. Somatic comorbidity included acute cor onary syndrome, other cardiovascular diseases, connective tissue disease, inflammatory disease, infectious disease, can cer, obesity, hypertension, chronic obstructive pulmonary dis ease, diabetes mellitus and migraine, whereas psychiatric co morbidity included anxiety, alcoholism, organic brain disorders (including dementia), nonaffective disorders, previ ous depression, use of lithium and poststroke/postentry de lirium. Finally, we included information on prescription of warfarin, clopidogrel and βblockers after study entry until the end of the first month (for early depression) or first year (for late depression) after study entry. The ICD10 and ATC codes used for definitions are shown in Appendix 1, Table S1 , available at jpn.ca. The covariates were chosen based on a pre vious analysis of covariates associated with inflammatory dis eases and depression following stroke. 2 The cardiac medica tion was chosen as it is assumed to reflect ASA and statin use after acute coronary syndrome and lithium owing to its use for bipolar depression. Anxiety (diagnosis of anxiety disorder, obsessive-compulsive disorder, stress reactions and sleep dis orders as well as use of anxiolytic drugs and sedatives), dia betes and cancer (diabetes and cancer related neuropathic pain) were also included as covariates, as these diseases are associated with depression and often treated with antidepres sant medication. Finally, from the Danish Stroke Registry, in cluding 45 765 patients, we obtained information on stroke severity based on the Scandinavian Stroke Scale. The scale ranges from 0 to 58 points and is based on ratings of con sciousness; eye movements; motor power in arms, hands and legs; orientation; speech; facial palsy; and gait. 
Statistical analysis
We used Stata software version 13.1 (StataCorp) for statistical analyses. All analyses were performed separately in stroke patients based on stroke subdiagnosis and in the nonstroke population. However, as the estimates differed only slightly across subdiagnosis, we chose to give the results for all strokes in a single category and included 1 analysis showing the results based on stroke subdiagnosis. Missing data (14% for education) were included as a fixed number. Study entry was the date of stroke event or the corresponding date for the nonstroke population. For earlyonset depression, individ uals were followed from the end of the first month after study entry until depression, death/emigration or the end of followup (1 year after stroke or study entry), whichever came first. Similarly, for lateonset depression, individuals were followed from the end of the first year after study entry until depression, death/emigration or the end of followup (Dec. 31, 2014) , whichever came first. Individuals who died/ emigrated, those who had an episode of depression during the first month after study entry were excluded.
We first tested whether having redeemed a prescription for ASA, NSAIDs or statins at the end of the first month after study entry was associated with decreased risk of earlyonset depression in both the stroke and the nonstroke population. We used Cox proportional hazards regressions with follow up time as the underlying time scale. All analyses were ad justed for covariates, which were entered in multiple regres sion models using the following stepwise approach. First, the basic sociodemographic characteristics (age, sex, education and cohabitation status) were entered. Then we added so matic comorbidity, other psychiatric comorbidity, previous depression and cardiac medication variables. This allowed us to see the influence of the different groups of covariates on the estimates. The proportional hazards assumption was tested graphically by plotting -ln[-ln(survival)] versus ln(followup time), and no violations were found. Further more, we used Kaplan-Meier curves to plot cumulative new events of both early and lateonset depression as a function of followup time.
Second, we tested if having redeemed a prescription for ASA, NSAIDs, or statins at the end of the first year after study entry was associated with decreased risk for lateonset depression in the stroke and in the nonstroke populations.
Third, we stratified individuals based on any combined treatment with ASA, NSAIDs and statins and examined how combinations of treatments were associated with the risk for early or lateonset depression in both populations. The refer ence group was individuals who did not receive any anti inflammatory treatment.
Fourth, we repeated the analyses of the combined treat ment with ASA, NSAIDs and statins, but stratified by stroke subtype in the stroke population.
Fifth, patients for whom data on stroke severity were avail able from the Danish Stroke Registry were divided into 2 groups based on stroke severity above or below the median (Scandinavian Stroke Scale score 49), and we examined the association between antiinflammatory treatment and early and lateonset depression separately in each group. Interac tion was tested using a likelihood ratio test by introducing a 2factor interaction term (medication use × severity) in the model.
In sensitivity analyses we accounted for individuals who died before depression could have developed using Fine Gray competing risk regression by the stcrreg command in Stata. Finally, we repeated the main analyses defining de pression only on the basis of ICD10 codes and not medica tion use.
Results
We identified 147 487 patients with firsttime stroke during the study period in the In the stroke population, the median duration of follow up was 365 (range 31-365) days for earlyonset depression and 5.5 (range 1.0-14.0) years for lateonset depression. During followup, earlyonset depression developed in 22%, whereas lateonset depression developed in 17%. For the nonstroke population the median duration of follow up was 365 (range 31-365) days for earlyonset depression and 6.2 (range 1.0-14.0) years in the analyses of late onset depression. During followup, earlyonset depression de veloped in 8%, and lateonset depression developed in 15%. Table 1 and Appendix 1, Table S2 show the distribu tion of the covariates in relation to ASA, NSAID, or statin use and depression outcomes in the stroke and nonstroke populations. Use of ASA and statins seemed strongly asso ciated with comorbidity, particularly in the nonstroke population.
Anti-inflammatory treatment and risk for early-onset depression
In the stroke population, individuals who had filled prescrip tions for ASA at the end of the first month after stroke had decreased risk of earlyonset depression, with a crude hazard ratio (HR) of 0.76 (95% confidence interval [CI] 0.74-0.78) compared with individuals who had not filled prescriptions for ASA (Fig. 1) . The corresponding HRs for NSAID and statin use at the end of the first month after stroke were 0.98 (Fig. 1) . Appendix 1, Figure  S1 shows Kaplan-Meyer plots of the time until early onset de pression in relation to ASA, NSAID, or statin use.
Anti-inflammatory treatment and risk for late-onset depression
In the stroke population, individuals who had filled pre scriptions for either ASA or NSAIDs at the end of the first year after study entry had increased risk for lateonset de pression, with Fig. 2 ). Appendix 1, Figure S2 shows Kaplan-Meyer plots of the time until late onset depression in relation to ASA, NSAID, or statin use.
Combined anti-inflammatory treatment and risk for earlyand late-onset depression
In the stroke population, individuals who had filled prescrip tions for either a single medication or a combination of the antiinflammatory medications at the end of the first month after stroke had decreased risk for earlyonset depression compared with individuals who had never filled prescrip tions for any of the medications. Individuals who had filled prescriptions for all 3 medications had the lowest risk, with a risk estimate of 0.63 (95% CI 0.60-0.67) after multiple adjust ments (Fig. 3) . In the nonstroke population, the correspond ing risk estimates suggested no effect of medication use, ex cept for the single use of NSAIDs, which was associated with a slightly increased risk for earlyonset depression (HR 1.10, 95% CI 1.05-1.15) after multiple adjustments. For lateonset depression, having filled prescriptions for 1 or more of the medications increased risk for lateonset depression in both the stroke and nonstroke populations, with the exception of single statin use, which was not associated with risk for late onset depression in the stroke population and further seemed to decrease the risk in the nonstroke population (Fig. 3) . In general, the risk estimates were slightly attenuated in the nonstroke population compared with the stroke population. All HRs for each of the covariates in the fully adjusted models are shown in Appendix 1, Tables S3-S6 .
Combined anti-inflammatory treatment and risk for earlyand late-onset depression stratified on stroke subtypes
Among the stroke population included, 8% had intracerebral hemorrhage, 39% had ischemic stroke, 47% had an unspeci fied stroke (either hemorrhage or infarction) and 6% had TIA. In general, all risk estimates indicated a decreased risk for earlyonset depression in individuals who had filled pre scriptions for either a single or a combination of the anti inflammatory medications, with the lowest risk estimates for ischemic stroke and the highest risk estimates for TIA (Fig. 4) . Risk estimates for hemorrhagic stroke and TIA had wider CIs because of the lower number of individuals in these groups, and risk estimates for TIA were not statistically significant. For lateonset depression, most risk estimates indicated an in creased risk for lateonset depression in individuals who had filled prescriptions for either a single or a combination of the antiinflammatory medications, with the highest risk esti mates for hemorrhagic stroke (Fig. 4 ). An exception was the single use of a statin, for which risk estimates indicated no 
Stroke severity, anti-inflammatory treatment and risk for early-and late-onset depression
Of the 45 765 patients with stroke in the Danish Stroke Regis ter, 8870 died or experienced an episode of depression before the end of the first month, leaving 36 895 patients with data on stroke severity at risk for earlyonset depression. When analyzed together, results from the stroke register were simi lar to the analyses in all patients combined (Fig. 5) . When stratified by stroke severity, risk estimates for earlyonset de pression were more pronounced in patients with more severe stroke than in patients with less severe stroke in association with ASA, NSAIDs and statins (p < 0.01 for all analyses). When examining risk for lateonset depression, after exclu sion of individuals who died or experienced an episode of depression (n = 21 048) before the end of the first year after stroke, 24 717 had data on stroke severity. Overall, results from the stroke register were similar to the results in the en tire stroke cohort (Fig. 5) . When we stratified for stroke sever ity, risk estimates were similar when examining prescriptions for ASA and NSAIDs, whereas statins were associated with a more pronounced decreased risk for lateonset depression in patients with less severe stroke (all p < 0.001).
Sensitivity analyses
Accounting for competing mortality risk using Fine Gray re gression did not change any conclusions (results not shown). Furthermore, when we defined depression only by ICD10 codes, results were similar, albeit slightly attenuated and with wider confidence intervals (Appendix 1, Tables S7 and S8) .
Discussion
This nationwide populationbased study showed that having filled a prescription for ASA, NSAIDs, or statins at the end of the first month after stroke decreased the risk of earlyonset depression (within the first year), paricularly in patients with more severe stroke. Combined treatment with all 3 types of medication decreased the risk further. Surprisingly, however, Risk for early-and late-onset depression (depression 1 month to 1 year after stroke/study entry or more than 1 year after stroke/study entry) after the combined use of acetylsalicylic acid (ASA), nonsteroidal antiinflammatory drugs (NSAIDs), or statins at the end of the first month or at the end of the first year after stroke/study entry. All analyses are adjusted for basic covariates (age, sex, education, and cohabitation status), somatic comorbidity (acute coronary syndrome, other cardiovascular disease, connective tissue disease, inflammatory disease, infection, cancer, obesity, hypertension, chronic obstructive pulmonary disease, diabetes mellitus, migraine), psychiatric comorbidity (anxiety, alcoholism, dementia, nonaffective disorders, lithium use, or delirium after stroke/study entry), previous depression (depression before stroke/ study entry), and medication use (warfarin, clopidogrel, and β-blockers after stroke/study entry). CI = confidence interval; HR = hazard ratio. ASA or NSAIDs prescribed at the end of the first year after stroke or study entry increased the risk for lateonset de pression in the stroke and in the nonstroke populations, whereas statin use seemed to decrease the risk for lateonset depression. Only 2 studies from 2014 analyzed the risk for depression after stroke, and both assessed statin use after stroke. One co hort study including 423 patients with ischemic stroke found that use of statins shortly after stroke was associated with re duced risk for depression 1 year after stroke. 15 In that study, depression was diagnosed based on a validated structured diag nostic interview; however, 32% of the baseline sample was lost to followup. The other study including 11 218 Chinese patients with incident stroke and TIA found that regular statin use (60 days within 6 mo of statin use) was associated with increased risk for depression 1 year after stroke.
14 How ever, that study did not account for comorbid diseases and previous depression. To date, no studies have examined the association between use of ASA or NSAIDs and depression after stroke. However, both types of antiinflammatory treat ment have been suggested to decrease the risk for depression in both observational studies and in randomized controlled trials. For ASA, most studies have been observational, and the results have been conflicting. [19] [20] [21] [22] [23] For NSAIDs, most studies have been randomized controlled trials that have suggested that the NSAID celecoxib decreases the risk for de pression. 24, 25 Among observational studies, a cross sectional study of 2800 healthy individuals found no association be tween NSAIDs and depressive symptoms, 26 whereas a large Danish study of 123 400 patients taking selective serotonin reuptake inhibitors (SSRIs) found that NSAID use increased the risk for depression. 21 These results are similar to those in our nonstroke population, in which NSAID use 1 month after study entry did not influence the risk for earlyonset depres sion, whereas NSAID use 1 year after study entry slightly in creased the risk for lateonset depression.
Mechanistically, our results support the hypothesis that in creased brain inflammation following the acute attack con tributes to the development of depression after stroke. 6 This could explain the inconsistent results for early and lateonset Risk for early-and late-onset depression (depression 1 mo to 1 yr after or more than 1 yr after stroke/study entry) after the combined use of acetylsalicylic acid (ASA), nonsteroidal antiinflammatory drugs (NSAIDs), or statins at the end of the first month (for early-onset depression) or at the end of the first year (for late-onset depression) after stroke/study entry in patients with stroke based on stroke subtype. All analy ses are adjusted for basic covariates (age, sex, education, and cohabitation status), somatic comorbidity (acute coronary syndrome, other cardiovascular disease, connective tissue disease, inflammatory disease, infection, cancer, obesity, hypertension, chronic obstructive pulmonary disease, diabetes mellitus, migraine), psychiatric comorbidity (anxiety, alcoholism, dementia, nonaffective disorders, lithium use, or delirium after stroke/study entry), previous depression (depression before stroke/study entry), and medication use (warfarin, clopidogrel, and β-blockers after stroke/study entry). CI = confidence interval; HR = hazard ratio. depression in patients with stroke and our findings on stroke severity. The increase in proinflammatory cytokines during the days to weeks following stroke may increase the risk for depression shortly after stroke, possibly through activation of indolamin 2.3dioxygenase and production of kynurenine in stead of serotonin. 6 Antiinflammatory medication, which limits this immediate increase in proinflammatory cytokines, may consequently lower the risk for early depression after stroke. Supporting this finding, patients with TIA and indi viduals in the nonstroke population did not experience the same benefit from antiinflammatory medication as patients with stroke, most likely because they did not have the same increase in brain inflammation seen in patients with stroke. Furthermore, risk estimates were more pronounced in pa tients with ischemic strokes than in patients with hemor rhagic strokes, perhaps because of a higher level of inflam mation in ischemic strokes. However, the estimates for hemorrhagic stroke were also less precise. Supporting this finding, a recent metaanalysis suggested that levels of in flammation are higher before ischemic than hemorrhagic strokes. 16 In addition, the largest effect of antiinflammatory medication was seen in patients with more severe stroke, suggesting a larger degree of tissue damage resulting in in creased inflammation levels.
Our results on lateonset depression could further support the hypothesis that this type of depression is less driven by inflammation and consequently that antiinflammatory medi cation does not protect against this type of depression. In fact, we found an increased risk for lateonset depression in individuals receiving ASA or NSAIDs, but not statins. This finding could have been caused by confounding by indica tion, as individuals taking antiinflammatory drugs may have been taking them for a condition that increases the level of inflammation or that is in other ways related to depres sion. Indeed, this seemed to be more evident in the nonstroke population, where comorbidities were more strongly associ ated with antiinflammatory treatment. Furthermore, the in dividuals who received both ASA and NSAIDs 1 year after Risk for early-and late-onset depression (depression 1 mo to 1 yr after or more than 1 yr after inclusion) after the combined use of acetyl salicylic acid (ASA), nonsteroidal antiinflammatory drugs (NSAIDs), or statins at the end of the first month (for early-onset depression) or at the end of the first year (for late-onset depression) after inclusion in the entire cohort and in patients with stroke with data from the Danish Stroke Register. All analyses are adjusted for basic covariates (age, sex, education, and cohabitation status), somatic comorbidity (acute coronary syndrome, other cardiovascular disease, connective tissue disease, inflammatory disease, infection, cancer, obesity, hypertension, chronic obstructive pulmonary disease, diabetes mellitus, migraine), psychiatric comorbidity (anxiety, alcoholism, dementia, nonaffective disorders, lithium use, or delirium after inclusion), previous depression (depression before inclusion), and medication use (warfarin, clopidogrel, and β-blockers after inclusion). CI = confidence interval; HR = hazard ratio. stroke were older and had more somatic and psychiatric comorbidities than individuals who did not receive anti inflammatory medication (data not shown).
Early-onset depression
Another explanation for our findings could be linked to the mechanism of the medications studied. In general, anti inflammatory medication has been proposed to exhibit anti depressant effects by decreasing neuroinflammation. 27, 28 How ever, some studies have suggested that inhibition of the cyclooxygenase (COX)1 and COX2 by ASA or NSAIDs may increase inflammation in the brain 29, 30 and augment oxidative and nitrooxidative stress, 27 which in turn may increase the risk for depression. Statins do not act through COX inhibition and thus do not increase the risk for depression through this pathway. This suggests a more complicated association be tween use of antiinflammatory agents and risk for depression.
After excluding patients with hemorrhagic stroke (for whom anticoagulant therapy is not recommended), only 67% of the patients with stroke who were still alive 1 year after stroke used ASA, and only 53% used statins even though statin therapy is recommended after ischemic stroke. This is in line with the findings of other studies reporting that not all patients are prescribed medical prophylaxis after stroke. 31 The patients who did not receive ASA during the first year after stroke were significantly more often women, were less likely to live alone and were less likely to have cardiovascular dis ease, diabetes or anxiety than patients who received ASA. Furthermore, they were significantly more likely to use other forms of anticoagulants, such as warfarin and clopidogrel. Patients with stroke who did not receive statins 1 year after stroke were similarly more likely to be women, but the so matic and psychiatric comorbidity was more equal between those receiving and those not receiving statins. Additionally, patients who did not receive statins were less likely to receive other forms of anticoagulants. These findings support the hy pothesis that the increased risk for lateonset depression in in dividuals receiving ASA could be caused by confounding.
Limitations
The strength of this study is the large sample, including all pa tients in Denmark with firsttime stroke between 2001 and 2011 based on information from the National Patient Register, which has high validity for stroke registration. 32 Also, we were able to include a nonstroke population and obtain information on comorbid disorders, medication use and stroke severity.
One limitation of the study is that we did not have infor mation on patients in whom depression was diagnosed out side hospitals if they did not fill prescriptions for antidepres sants. Such an assumed random misclassification could have diluted our risk estimates. In addition, the study did not in clude overthecounter (i.e., nonprescription) medication. Both ASA and NSAIDs can be bought without prescriptions, whereas statins and antidepressant medications can only be bought with a prescription. However, patients with regular use of ASA or NSAIDs would probably buy it on prescrip tion, as they then receive a 50% refund of the cost. In addi tion, all contacts with the health system, including prescrip tions, are free of charge. Thus, the proportion of over the counter medication use among our study population was probably small. Another limitation to our study is that pre scription of antidepressant medication was used as a proxy for depression, which is not always accurate. For example, SSRIs are often prescribed for other illnesses, such as anxiety and obsessive-compulsive disorder, and tricyclic antidepres sants may be prescribed for neuropathic pain. However, all analyses were adjusted for anxiety; obsessive-compulsive disorder; sleep disorders; use of anxiolytics, hypnotics and sedatives; diabetes; and cancer (the latter 2 comorbid illnesses are often associated with neuropathic pain). When we de fined depression based only on ICD10 codes, results were similar. Finally, another limitation was the fact that we had no information on inflammatory levels, smoking, or other risk factors, such as lifestyle factors, in our population, which might have confounded our risk estimates.
Conclusion
Our study provides some evidence that antiinflammatory treatment after stroke might be associated with a lower risk for earlyonset depression, possibly by inhibiting the release of inflammatory cytokines. On the other hand, we found that ASA and NSAID use increased the risk for lateonset depres sion, which could be explained by confounding by indication or mechanistically by their effect on the COX and augmenta tion of nitrooxidative and oxidative stress. Our study sug gests that depression within the first year after stroke is driven by increased inflammation in the brain following stroke and stresses the importance of antiinflammatory treatment with ASA and statins immediate after stroke, as this may not only prevent a new stroke event, but also pre vent earlyonset depression. Our study also stresses the need for more research on the potential negative effects of anti inflammatory drugs on the risk for depression.
